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Abstract
Background: The thermogenic and metabolic properties of capsinoids appear to mimic those of the more
pungent sister compound capsaicin. However, few data exist on how capsinoid ingestion affects energy
expenditure in humans and no data exist on its interaction with exercise. We aimed to determine how ingestion of
capsinoids affected energy expenditure, lipid oxidation and blood metabolites at rest and during moderate
intensity exercise.
Methods: Twelve healthy young men (age = 24.3 ± 3 yr, BMI = 25.5 ± 1.7 kg·m
-2) were studied on two occasions
in a double-blind design following ingestion of either placebo or 10 mg of purified capsinoids at rest, after 90 min
of cycling at 55% VO2 peak, and for 30 min into recovery. Subjects ingested the capsules 30 min prior to exercise.
Results: At rest, following ingestion of capsinoids, we observed increases in VO2 and plasma norepinephrine levels,
and decreases in concentrations of serum free fatty acids, plasma glycerol and the respiratory exchange ratio (all P
< 0.05). At exercise onset, we observed a blunted accumulation of blood lactate with capsinoid ingestion vs.
placebo (P < 0.05). There were no other significant differences between the conditions during or post-exercise.
Conclusion: The ingestion of 10 mg of capsinoids increased adrenergic activity, energy expenditure, and resulted
in a shift in substrate utilization toward lipid at rest but had little effect during exercise or recovery. The changes
we observed confirm previous data on the thermogenic and metabolic effects of capsinoids at rest and further
promote its potential role as an adjunct weight loss aid, in addition to diet and exercise.
Introduction
Capsinoids are non-pungent analogues of capsaicin
derived from the CH-19 sweet pepper [1]. Ingestion of
capsinoids have been shown in most studies [2-5] but
not all [6] to increase resting oxygen consumption, body
temperature, and lipid oxidation in humans. As such,
capsinoids appear to act in a manner similar to that of
many adrenergic system agonists [2-4]. A major differ-
ence, however, is that capsinoids are broken down in
the intestinal tract to yield vanillyl alcohol and a fatty
acid [7-9]. This implies that the mechanism by which
capsinoids work is likely neurally mediated via the vanil-
loid receptor (TRPV1) and gastric and intestinal neurons
which trigger a centrally-mediated adrenergic response
[7]. Capsinoids and capsaicin affect metabolism and
thermogenesis in similar ways, but there are relevant
differences. For example, capsaicin, due to its pungency
and thus its additional effects on nociceptors [7], has
been shown to increase blood pressure and heart rate
shortly after ingestion whereas capsinoids do not [2].
Thus, given the complete lack of pungency, the use of
capsinoids may represent a more viable longer-term
adjunct therapy for the treatment of overweight and
obesity as it has been shown to be effective in prevent-
ing weight gain in humans [3,4].
Obesity-related programs that do not involve pharma-
cological interventions advocate the use of diet and/or
exercise as treatment [10-13]. One of the biggest detrac-
tions of diet-induced weight loss is a reduction in rest-
ing metabolic rate [11,12], which has been counteracted
by the use of adrenergic drugs [14-16]. These drugs
increase metabolism; however, their side-effect profiles
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Despite this health risk, it has been well documented
that thermogenic agents are used with great frequency
by people attempting to lose weight [19] and can even
be done so effectively [20]; however, a lower side-effect
burden would likely be beneficial.
Capsinoids are non-pungent thermogenic compounds
that promote lipid oxidation, and as mentioned have a
very favourable toxicity and side-effect profile [1]. Thus,
capsinoids could be used to support diet and/or exer-
cise-induced weight loss in the treatment of overweight
and obesity [2-5]. With this in mind, it would be impor-
tant to test this compound in a clinical setting to deter-
mine its efficacy as an adjunct weight loss aid. As a
preliminary step, we set out to test capsinoids in con-
junction with exercise to see if the thermogenic and
metabolic effects at rest are maintained or even poten-
tiated with exercise. Thus, the purpose of this study was
to examine the response of young healthy males to a 90
min bout of moderate intensity endurance exercise after
having consumed 0 mg (placebo) or 10 mg of capsi-
noids. We proposed that capsinoid ingestion 30 min
p r i o rt oe x e r c i s ew o u l dg e n e r a l l yi n d u c em e t a b o l i c
changes consistent with increased metabolic rate and
lipid oxidation, namely: elevate resting oxygen consump-
tion; a shift in metabolism (r e s p i r a t o r ye x c h a n g er a t i o
[RER]) towards greater lipid oxidation; and increase
catecholamine release consistent with a stimulation of
the adrenergic system. We further hypothesized that the
aforementioned changes would be maintained with
moderate exercise.
Methods
Subjects
Young healthy males between the ages of 18 and 30
years were recruited from McMaster University and the
surrounding Hamilton area. All participants were
screened prior to inclusion for standard medical condi-
tions that would preclude their participation in the trial.
Subjects were deemed healthy based on their responses
to the medical screening questionnaire and thus were
eligible to participate. Subjects were also required to be
recreationally active defined as exercising at least 2
times, but no more than 5 times per week, and have a
peak VO2 of > 40 ml/kg/min as determined by a maxi-
mal progressive exercise test. Exclusion criteria included
smoking and the use of interfering medications, natural
health products or dietary supplements.
Subjects were informed of the potential risks and
procedures associated with the study and gave their
written informed consent prior to participation.
The protocol was approved by the Research Ethics
Board at McMaster University and Hamilton Health
Sciences and conformed to all standards of Canada’s
Interagency Panel on Research Ethics for conducting
human research http://www.pre.ethics.gc.ca/eng/index/.
The capsinoids also underwent review by Health Cana-
da’s Natural Health Products Directorate (NHPD) and
a notice of authorization was obtained (NHPD #
130269) before ethics approval was granted.
Test substance
Capsules contained an extract from the pepper fruit
variety CH-19 Sweet. (Capsicum anuum L.). Capsinoid
oil was extracted as follows: the dried fruit was treated
with hexane, and fruit sediment was removed by filtra-
tion, followed by evaporation and distillation with med-
ium-chain triacylglycerol and column chromatography
to yield purified capsinoids. Capsinoids consisted of
capsiate, dihydrocapsiate and norhydrocapsiate in a
70:23:7 ratio (as determined by High Performance
Liquid Chromatography [HPLC]). The purified capsi-
noids were then dissolved in rapeseed oil and encapsu-
lated in vegetarian softgel capsules made of modified
maizestarch, vegetable glycerine and carageenan; each
capsule contained 1 mg of capsinoids and 199 mg of a
mixture of rapeseed oil and medium-chain triacylglycer-
ols. All capsules were manufactured in one batch. Stabi-
lity tests determined that the product would be stable
beyond the duration of the trial.
Protocol
Conditions
We used a double-blind, placebo-controlled, repeated
measures study design in which each subject completed
2 trials; 0 mg and 10 mg of capsinoids in random order.
Based on the acute results of previous studies [2,4], we
anticipated that a sample size of 12 subjects (all male; to
control for possible sex-based differences in substrate
oxidation during exercise) would be adequate to see sig-
nificant effects of capsinoids on oxygen consumption
and substrate oxidation. Capsinoids were ingested in
capsule form. All capsules looked identical and con-
tained either 1 mg of capsinoids or not (rapeseed oil
only). Ten small capsules were consumed at each trial.
Subjects were instructed to consume the capsules in 1
minute when given and were allowed water throughout
the trial ad libitim. McMaster University Pharmacy con-
trolled the randomization and the code for each treat-
ment was given to the principal investigator only after
completion of the data analysis.
Pre-trial testing
Peak VO2 test Once informed consent was obtained,
subjects were asked to come to the Exercise Metabolism
Research Group (EMRG) laboratory at McMaster Uni-
versity to establish their peak VO2 using an incremental
ramp protocol on a braked cycle ergometer (Lode, Gro-
ningen, The Netherlands). Subjects rode at 75W for 2
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gressively increased 0.5 W/s until the subject could no
longer continue. Criteria for stopping the VO2 peak test
included, a) failure to maintain a cadence of 60 rpm; b)
reached within 10% of calculated maximal heart rate
(220 - age); c) had an RER > 1.15. Failure to meet these
criteria meant the subject did not reach their peak oxy-
gen consumption and was required to repeat the test.
All 12 subjects achieved their peak VO2 in one test.
Familiarization ride Once the subject’s peak VO2 was
established, they were asked to return to the EMRG
laboratory for an additional pre-trial ride where we
aimed to verify the workload corresponding to 55% of
each subject’sp e a kV O 2. This exercise intensity is ade-
quate to elevate lipolysis (i.e., increase circulating gly-
cerol and FFA), catecholamines, and show a substantial
shift in RER toward lipid oxidation with increasing exer-
cise duration [21-23]. Moreover, this type of exercise
intensity represented an intensity that elicited an exer-
cising RER at or around 0.85, a level at which a good
blend of fuels are being oxidized, but is also an intensity
close to what has been referred to as ‘fatmax’,w h i c hi s
defined as the intensity of exercise at which the maximal
rate of lipid oxidation occurs [19,24-26]. Before the test,
we calculated this workload according to the algorithm
detailed by Latin et al. [27], and had subjects pedal just
below (-10 W), at, and just above (+10 W) the calcu-
lated workload while measuring VO2, VE and HR during
the ride. This ride took ~30-40 minutes to complete; 10
min at each workload. A successful test occurred when
the workload that elicited a VO2 of 55 ± 1% of the mea-
sured peak VO2 was achieved. The workload established
during this test was then to be the workload the subject
pedaled at during the trials. Following the successful
ride, we recorded the seat and handle bar settings which
felt most comfortable in order to have the bike ready
for the subject on subsequent trial days.
Testing
Trial days Subjects reported to the lab twice in the
morning for their trials at either 0700 h, 0900 h or 1100
h. Exercise trials took place after an overnight fast of
10-12 hours. Subjects recorded their evening meal the
night before the first trial, and in order to standardize
pre-trial conditions, subjects were asked to consume the
same meal the night before the next trial. Having sub-
jects in the fasted state does not present a risk or barrier
to the subjects completing the trial as based on past
experience with this protocol [21,23,28]. Moreover,
being in the fasted state during exercise is, from a
mechanistic standpoint, the easiest state in which to
interpret the data on substrate oxidation. Subjects were
also asked to refrain from consuming alcohol and caf-
feine the night before (from 1800 h onwards) the trial.
Trials were separated by 1 week, thus each subject was
to maintain the same trial time and day of the week for
2 weeks in order to complete the study.
Upon arrival to the lab, subjects were asked to sit
and relax (~30 min) to become acclimatized to the
room before the first blood sample was taken. Also
during this time, subject’s weight was taken and several
questions pertaining to sleeping patterns, food con-
sumption and medication use from the previous day
were answered. The trial then proceeded according to
the schematic timeline shown in Figure 1. Ambient
temperature in the lab was 22 ± 1ºC and relative
humidity was always less than 50%. Baseline heart rate
(HR), metabolic cart measures (VO2,V C O 2,R E R ,V E )
and a blood sample were then taken. After 30 minutes
(noted as time 0 min; Figure 1), subjects’ ingested 10
small (1 mg each) gel capsules according to their
respective randomization allocation (0 mg or 10 mg of
capsinoids) with water ad libitim.A t3 0m i n u t e sp o s t -
ingestion (60 minutes into protocol), subjects started
cycling. They rode for 90 minutes at 55% of their peak
VO2 (as previously determined) and recovered for 30
minutes. HR, blood samples and metabolic cart mea-
surements were taken at several time points during the
ride and into recovery (Figure 1). The whole trial
lasted 180 minutes.
Analyses
Expired Gas Analysis
We collected expired gas samples (breath-by-breath and
ensemble averaged into 30s bins) using a metabolic cart
(AEI Technologies, Moxus respiratory gas analyzer,
Pittsburgh, PA) at several time points during and also
30 min into recovery to assess ventilation (VE), oxygen
uptake (VO2), carbon dioxide production (VCO2)a n d
respiratory exchange ratio (RER).
Blood Metabolites
Blood samples were taken in two Vacutainer tubes per
time point, one with sodium heparin and the other with
no additives to obtain plasma and serum, respectively.
Samples were subsequently processed and stored in -20°
C freezers for later analysis. Whole blood was also
immediately analyzed for blood glucose (Accu-Check,
Roche Diagnostics Canada, Laval, PQ) and blood lactate
(Accu-Trend, Roche Diagnostics Canada, Laval, PQ).
Upon study completion, samples were then analysed for
various metabolites. All samples were analyzed in dupli-
cate and inter-sample coefficients of variation never
exceeded 5%. Plasma was analyzed for glycerol using a
fluorometric assay system based on the procedures out-
lined in detail elsewhere [21,22]. Serum free fatty acids
were analyzed using a commercially available kit (HR
Series NEFA-HR(2), Wako Diagnostics, Richmond, VA).
Plasma treated with glutathione was analyzed for con-
centrations of epinephrine and norepinephrine using
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sis as described previously [21].
Rate of Perceived Exertion
We measured subject’s perceived exertion during the exer-
cise with a validated visual analogue scale (Borg Scale).
Statistics
All data were analyzed using a repeated measures two-
way analysis of variance (ANOVA) with time as a within
factor and dose as a between factor. Significant ANOVA
effects were further analyzed using Tukey’st e s ta sa
post-hoc procedure; P < 0.05 was deemed to be signifi-
cant. Changes in resting values from pre- to post-capsi-
ate/placebo ingestion were compared using a paired
t-test. Values are presented means ± SD, n = 12 per
data point unless otherwise noted.
Results
Subject characteristics
Twelve male subjects participated in this study. Subject
characteristics are shown in Table 1. Subjects were all rela-
tively fit with a mean peak VO2 of 43.3 ± 2.1 ml/kg/min.
Oxygen Consumption and Respiratory Exchange Ratio
(VO2 and RER)
No differences were observed between treatments for
VO2 or RER during the trial (Figures 2a and 2b).
Examination of the resting values only (-30 to 30 min of
protocol), we observed that resting VO2 was significantly
higher and resting RER was significantly lower following
ingestion of 10 mg of capsinoids versus baseline and
0m g( Figures 2c and 2d). When expressing the meta-
bolic rate (l/min) as kcal/min, the resulting resting
values pre and post ingestion were: placebo at rest:
1.54 kcal/min to 1.64 kcal/min; capsinoid at rest:
1.49 kcal/min to 1.83 kcal/min.
Heart Rate (HR) and Rating of Perceived Exertion (RPE)
We observed the expected rise in exercise HR in all sub-
jects, but did not observe any differences between trials
at rest or during exercise. Similarly, we did not see any
differences between trials in subjects’ rating of perceived
exertion (data not shown).
Blood Metabolites
Blood glucose remained stable and unchanged through-
out all phases of the protocol, including rest, with no
significant difference between conditions (Figure 3a). At
rest and during the last hour of the protocol, no differ-
ences between groups were observed in blood lactate
concentrations. There was no observed rise in lactate
levels during the trial following the consumption of cap-
sinoids. Thirty minutes into exercise (at 60 min), blood
lactate levels were significantly elevated compared to
rest (30 min) in the placebo group only (Figure 3b).
Concentrations of serum FFAs and plasma glycerol
increased in both trials to a similar extent after the
onset of exercise (Figures 4a and 4b). Upon examina-
tion of the resting values only (-30 to 30 min of proto-
col), serum FFAs and plasma glycerol were significantly
reduced at 30 min compared to starting levels (-30 min)
following ingestion of 10 mg of capsinoids only. No
changes were observed in the placebo group (Figures 4c
Figure 1 Schematic representation of the protocol to test the impact of capsinoids on resting and exercising energy expenditure.V O 2
- oxygen consumption, VCO2 - carbon dioxide production, VE - ventilation, HR- heart rate and RPE - rate of perceived exertion (according to
Borg’s scale). Capsinoids/placebo ingestion occurred at 0 min.
Table 1 Subject characteristics
Age (yr) 24 ± 3
Weight (kg) 83.0 ± 10.5
Height (m) 1.80 ± 0.08
Body Mass Index (kg
.m
-2) 25.5 ± 1.7
Peak VO2 (ml/kg/min) 43.3 ± 2.1
Peak VO2 (l/min) 3.58 ± 0.44
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(indirectly using RER and VO2), the resulting resting
values pre and post ingestion were: placebo at rest: 1.18
kcal/min to 1.26 kcal/min; capsinoid at rest: 1.19 kcal/
min to 1.41 kcal/min. The responses of plasma norepi-
nephrine and epinephrine are show in Figures 5a and
5b, respectively. Overall, there were no differences
between trials in the adrenergic hormones. When look-
ing only at the resting time points (-30 min and 30
min), plasma norepinephrine concentrations were signif-
icantly higher at 30 min compared to -30 min following
ingestion of 10 mg of capsinoids but not placebo
(Figure 5c). There was no change in plasma epinephrine
at rest.
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Figure 2 Oxygen uptake during the protocol from the time of ingestion. (a). Respiratory exchange ratio (RER) during the protocol from the
time of ingestion (b). Oxygen uptake at rest only; measured at -30 min and 30 min (c). Inset c represents the change in resting VO2. RER at rest
only measured at -30 min and 30 min (d). Inset d represents the change in resting RER. * Significantly different (P < 0.05) from the same value at
rest or than the other condition (inset). ↓ Ingestion of capsinoids/placebo at 0 min. Values are means ± SD (n = 12).
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The average ad libitim water intake during the trial was
~1L (2 × 500 ml water bottles) with no differences
between groups. No subject reported feeling any differ-
ent (i.e. increased HR, sweating, breathing rate, etc.)
between the trials.
Discussion
T h em a i nf i n d i n g so ft h i si n v estigation were that, ver-
sus a placebo, 10 mg of capsinoids induced a rise in
resting oxygen consumption, a decline in RER, an
increase in plasma norepinephrine, and a decline in
serum FFAs at rest. We also observed that 10 mg of
capsinoids blunted the small but significant rise in
blood lactate observed at the onset of exercise seen in
the placebo group (0 mg).
Our original hypothesis was that we would see the
aforementioned changes in VO2, RER and catechola-
mines at rest, in line with previous studies [2-4], and
that these differences would carry over and be main-
tained or even augmented during exercise. This type of
response has been observed with another adrenergic
agonist, caffeine [29]. We did not observe this response
and, in fact, aside from the slightly lower blood lactate
seen with capsinoid ingestion there was no effect at rest
that carried over into exercise. Thus, we propose that
the usual adrenergic response associated with exercise
may have been greater than that which was induced by
capsinoids at rest thereby overriding any significant dif-
ferences seen during the exercise phase. Hence, there
was no synergistic or additive effect at this intensity of
exercise. Figure 5 shows that the increases seen in
plasma epinephrine and norepinephrine during exercise
far exceed the magnitude of increase seen at rest with
10 mg of capsinoids. Therefore, it is not surprising that
these subtle differences between treatments disappeared
with exercise. Our findings do, however, further support
claims that capsinoids have their greatest thermogenic
effect at rest.
The consumption of 10 mg of capsinoids resulted in a
rise in plasma norepinephrine and a decline in RER.
Both of these findings suggest that capsinoids increased
whole-body lipid oxidation at rest. Furthermore, both
plasma glycerol and serum FFA concentration decreased
concomitantly possibly indicating the body’s increased
reliance on circulating lipids as fuel at that time; without
tracer-based estimates of appearance and disappearance
w ea r eu n a b l et oc o n f i r mo u rt h e s i s .S i m i l a rf i n d i n g s
with respect to lipid metabolism were reported in a
longer term study by Kawabata et al [3]. Researchers fed
human subjects CH-19 sweet peppers (0.13 g/kg before
each meal [0.4 g/kg total]) for 2 weeks and controlled
their diet. Those who consumed capsinoids showed a
decrease in visceral fat (assessed by CT scan), a decrease
in resting RER, and a significantly greater weight loss
compared to the control group. Moreover, there was a
significant correlation bet w e e nw e i g h tl o s ta n dS N S
activity (R
2 = 0.66; P < 0.05) [3]. In a more recent study,
80 overweight men and women were fed 6 mg/d of cap-
sinoids or placebo for 12 weeks. While total body weight
and % body fat did not differ between groups, the capsi-
noid group showed reductions in visceral fat assessed by
DXA and increases in fat oxidation assessed by indirect
calorimetry [5]. While these studies certainly show evi-
dence for capsinoids being adrenergic system stimulants
and activating lipid oxidation, they do little to shed light
on a potential mechanism. As previously mentioned, tra-
cer-based measures are required to assess the mechanis-
tic underpinnings responsible for the decline in RER
and increased lipid oxidation and visceral fat loss with
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Figure 3 Blood glucose (a) and lactate (b) concentrations during
the protocol from the time of ingestion. *Significantly different (P <
0.05) from rest (30 min) in the placebo group only. ↓ Ingestion of
capsinoids/placebo at 0 min. Values are means ± SD (n = 12).
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Page 6 of 10capsinoids. With respect to capsinoids’ positive effect on
the sympathetic nervous system (SNS), this phenom-
enon has been demonstrated consistently in other
human studies [2-4].
We also observed an increase in metabolic rate as
indicated by the increase in resting VO2 with the con-
sumption of capsinoids. Our findings are similar to
most [2,4] but not all [6] of those reported previously in
humans showing increased oxygen consumption and
heat production indicative of SNS activation. Moreover,
as also reported previously [2], we demonstrated that
capsinoids did not affect resting heart rate measures
despite the observed changes in plasma norepinephrine
and energy expenditure. In a study by Ohnuki et al. [4],
increases in resting oxygen consumption were reported
to be in the range of ~5% with consumption of 0.1 g/kg
of CH-19 sweet peppers (i.e. for a 70 kg male, this cor-
responds to 7 g of CH-19 sweet peppers and ~5 mg
purified capsinoids [0.3-1.0 mg capsinoids/g pepper
[4]]). We report here that 10 mg of purified capsinoids
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Figure 4 Serum free fatty acids (FFA; a) and plasma glycerol (b) concentrations during the protocol from the time of ingestion. Serum
FFA at rest only; measured at -30 min and 30 min (c). Inset c represents the change in resting FFA concentration. Plasma Glycerol at rest only;
measured at -30 min and 30 min (d). Inset d represents the change in resting glycerol concentration. * Significantly different (P < 0.05) from the
same value at rest or than the other condition (inset). ↓ Ingestion of capsinoids/placebo at 0 min. Values are means ± SD (n = 12).
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Page 7 of 10extracted from CH-19 sweet peppers, a much larger
dose, induced a significant rise in resting oxygen con-
sumption of a little more than 20% or 70 ± 13 ml/min.
Therefore, the increase in resting VO2 observed in our
study, although greater in magnitude possibly due to the
larger dose, seems to be in line with other published
research [2,4]. Although we did not measure core body
temperature in the current study, with a dose of 0.1 g/
kg of CH-19 sweet peppers, researchers observed a sig-
nificant increase in core body temperature 10-60 min
post ingestion further supporting an increase in thermo-
genesis with capsinoids [4].
This study was the first to assess the effect of capsi-
noids and aerobic exercise together in humans on
measures of substrate oxidation and energy expenditure.
None of the observed resting differences between groups
were maintained with exercise. However, at the onset of
exercise, the ingestion of 10 mg of capsinoids blunted
the rise in blood lactate observed in the placebo group,
although significant, this effect was quite subtle. A num-
ber of mechanisms are thought to affect lactate produc-
tion and clearance during exercise, especially at the
onset. These include oxygen availability, pyruvate dehy-
drogenase activation, lactate dehydrogenase isozymes, as
well as lactate transporter content [30]. While we can-
not be entirely sure as to why lactate did not increase to
t h es a m ee x t e n ti nb o t hg r o u p sa tt h es t a r to fe x e r c i s e ,
we speculate that it may be due to an increased reliance
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Figure 5 Plasma Epinephrine (Epi; a) and norepinephrine (Norepi; b) concentrations during the protocol from the time of ingestion.
Norepinephrine concentrations at rest only; measured at -30 min and 30 min (c). Inset c represents the change in resting norepinephrine. *
Significantly different (P < 0.05) from the same value at rest or than the other condition (inset). ↓ Ingestion of capsinoids/placebo at 0 min.
Values are means ± SD (n = 12).
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Page 8 of 10by the 10 mg capsinoids group on available FFAs as fuel
early in exercise as opposed to glycogen. Although quite
plausible, further studies would need to confirm this
hypothesis.
The results of the current study lead us to believe that
capsinoids’ effects on resting metabolism do not carry
over into exercise. It is entirely possible, however, that
our exercise regimen may have been too intense and
that a lower intensity exercise such as a fast-paced walk
would have allowed us to see maintenance of some of
the resting metabolic and thermogenic effects. Further
studies are needed to assess this, possibly implementing
an exercise regimen that more closely mimics daily rou-
tines of the general North American population, i.e.
activity that is less strenuous and shorter. It would also
be interesting to test the effect of capsinoids with a
45-60 minute brisk walk and to monitor for 1 hour
post-exercise to allow for a more complete metabolic
recovery. Moreover, a test of the effect of capsinoids
under these conditions in overweight and obese, seden-
tary persons may reveal effects during exercise not seen
in fit, normal weight individuals.
In conclusion, 10 mg of purified capsinoids resulted in
increased thermogenesis following ingestion in young,
healthy, physically active males. In this crossover, dou-
ble-blind, acute trial, compared to a placebo, capsinoids
increased resting energy expenditure by ~20%, and
based on several observations relating to lipid metabo-
lism (decreased RER, decreased levels of FFAs and gly-
cerol in blood, increased SNS activity), capsinoid
ingestion induced greater lipid oxidation at rest.
Although none of these effects carried over into exer-
cise, the blunted lactate response with capsinoids
30 min into the exercise bout suggests an altered sub-
strate use, namely a greater reliance on fat as fuel, at the
start of exercise. This study, in conjunction with the
current literature, further proves that the subtle meta-
bolic effects of capsinoids are most pronounced at rest
and as demonstrated in this trial, they seem to be super-
seded by a moderate exercise regimen.
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